Werkgroep Cardiologische centra Nederland

BalanceD-HF (Recruiting)

a Phase III, randomised, Double-blind study to evaluate the effect of Balcinrenone/Dapagliflozin, compared with dapagliflozin, on the risk of heart failure events and cardiovascular death in patients with heart failure and impaired kidney function
Medicine
Balcinrenone/Dapagliflozine
Population
Heart failure
Phase
III
Starting year
2023

Director of Study

S. Assa (Cardioloog)
Emmen, Treant Zorggroep, locatie Scheper